Mereo BioPharma announces Positive Top-Line Efficacy and Safety Data from “ASTRAEUS” Phase II Trial of Alvelestat in Alpha-1 Antitrypsin Deficiency- associated Emphysema

Mereo BioPharma Group plc announced positive top-line efficacy and safety results from “ASTRAEUS” a Phase II study of the investigational oral neutrophil elastase inhibitor, alvelestat, in patients with severe alpha-1 antitrypsin deficiency-associated emphysema.